Le Lézard
Classified in: Health
Subjects: PDT, TDS

Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World


THE HAGUE, Netherlands, April 30, 2024 /PRNewswire/ -- The 12th Microbiome and Probiotics R&D and Business Collaboration Forum was held with great fanfare in The Hague, Netherlands from April 23rd to 24th, 2024. This prestigious conference is a leading event in the probiotics sector, drawing together a diverse array of experts, scholars, and industry leaders from worldwide.

As a pioneer in the commercial application of probiotics in China, Ambpomial, a yogurt brand with a national reputation, was honored with an invitation to such a prestigious event as the Official Yogurt Provider. With a world-first breakthrough, Ambpomial's ambient-stable yogurt has achieved a significant leap in the field of probiotic yogurt production by overcoming the long-standing technical challenge of probiotic inactivation in ambient yogurt, thus becoming a highlight of the forum. Ambpomial has successfully incorporated 1 billion CFU of the globally renowned active probiotic strain, Lactobacillus rhamnosus GG, into each bottle of yogurt. Ambpomial's ambient-stable yogurt is better aligned with the Chinese preference for warm food, offering consumers a healthier and more delicious option.

Dr. Gerrit Smit, Managing Director from Yili Innovation Center Europe of Yili Group stated at the forum that Ambpomial's ADI technology, which means addition process of specific probiotics after product sterilization, results from five years of preparation, two years of intensive research, and over a hundred innovative experiments. This technological milestone has overcome several scientific barriers, such as probiotic inactivation in ambient yogurt, product post-acidification, and packaging swelling, thus pioneering the industry.

Dr. Erwin Gerard Zoetendal, an academic in gut microbiota, and Mr. Lars Bredmose, an expert from Novonesis, also weighed in on Ambpomial's technology breakthrough at the forum. They believe that this technology holds immense potential for future applications.

During the forum, Ambpomial invited a young scholar from China in probiotics to have on-site exchanges with European universities and probiotic companies. By providing industry-university research resource links for young academic groups, Ambpomial is also helping to cultivate core talents in probiotics in China. With the company's scientific research investment, Ambpomial is using innovation to promote the industry's long-term development. Recently, Ambpomial made an international appearance on the cover of Dairy Industries International magazine. Taking these as a new starting point, Ambpomial continues to craft and optimize probiotic yogurt products, aiming to be the pioneer brand in healthy yogurt, and bringing new growth opportunities to the dairy market.

SOURCE Yili Group


These press releases may also interest you

at 21:07
Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010...

at 20:51
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...

at 20:30
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...

at 20:05
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...



News published on and distributed by: